Mubritinib

{{Drugbox | IUPAC_name = 1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole | image = Mubritinib 2.svg | width = 250

| tradename = | pregnancy_category = | legal_status = Uncontrolled | routes_of_administration = Oral

| bioavailability = | metabolism = | elimination_half-life = | excretion =

| C=25 | H=23 | F=3 | N=4 | O=2 | molecular_weight = 468.47 g/mol | smiles = FC(F)(F)c1ccc(cc1)\C=C\c2nc(co2)COc3ccc(cc3)CCCCn4nncc4 }}

Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.^[1]^[2]^[3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.^[4]

Synthesis

References

^ McCormick, Frank; Doriano Fabbro (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. ISBN 1-58829-384-X.
^ Mitscher, Lester A.; Lednicer, Daniel (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.
^ Lednicer, Daniel (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 0-470-19039-6.
^ "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 - Full Text View - ClinicalTrials.gov".

[isbn1-58829-384-X-1] McCormick, Frank; Doriano Fabbro (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. ISBN 1-58829-384-X.

[isbn0-470-10750-2-2] Mitscher, Lester A.; Lednicer, Daniel (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.

[isbn0-470-19039-6-3] Lednicer, Daniel (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 0-470-19039-6.

[urlSafety_and_Tolerability_Study_of_TAK-165_in_Subjects_With_Tumors_Expressing_HER2_-_Full_Text_View_-_ClinicalTrials.gov-4] "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 - Full Text View - ClinicalTrials.gov".

[1]

[2]

[3]

[4]

Synthesis

See also

References